PharmaShots | Incisive News in 3 Shots

Subscribe Now

Stage III

AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval for Unresectable Stage III Non-Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) Receives NMPA's Approval for Unresectable Stage III Non-Small Cell Lung Cancer

December 12, 2019

Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell Lung Cancer (NSCLC)

Merck's Keytruda (pembrolizumab) Receives FDA's Expanded Monotherapy Label Approval for Patients with 1L Stage III Non-Small Cell...

April 12, 2019

Merck's Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults

Merck's Keytruda (pembrolizumab) Receives EU Approval for Resected Stage III Melanoma in Adults

December 18, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us